| Literature DB >> 35807603 |
Yejin Kim1, Jaeyoon Kim1, So-Ri Son1, Ji-Young Kim1, Jung-Hye Choi1, Dae Sik Jang1.
Abstract
The flower of Pueraria lobata (Puerariae Flos) is a reddish-purple to violet-purple flower that blooms between July and September. In our preliminary study, Puerariae Flos extract exhibited significant activity against a human ovarian cancer cell line. This research aims to identify the active compounds in Pueraria Flos. By repeated chromatography, one new tryptophan derivative (1), two new flavanones (4 and 5), and 19 known compounds, including tryptophan derivatives (2 and 3), flavonoids (6-9), isoflavonoids (10-20), a flavonolignan (21), and a phenolic compound (22), were isolated from a methanol extract of Puerariae Flos. The structures of new compounds were elucidated as 13-N-benzoyl-l-tryptophan-1-N-β-d-glucopyranoside (1), 2-hydroxy-5-methoxy-naringenin (4), and 2-hydroxy-5-methoxy-naringenin 7-O-β-d-glucopyranoside (5). Among the isolates, afromosin (17), tectorigenin (11), apigenin (8), glycitein (16), (-)-hydnocarpin (21), irilin D (12), irisolidone 7-O-glucoside (14), and genistein (10) showed cytotoxicity against human ovarian cancer cell line A2780. Apigenin (8) and (-)-hydnocarpin (21) were the most active (IC50 values of 9.99 and 7.36 μM, respectively).Entities:
Keywords: Pueraria lobata; Puerariae Flos; cytotoxicity; flavonoids; ovarian cancer; tryptophan derivatives
Year: 2022 PMID: 35807603 PMCID: PMC9269118 DOI: 10.3390/plants11131651
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Structures of compounds 1–22 isolated from Puerariae Flos.
1H- and 13C-NMR spectroscopic data of compound 1 (δ in ppm, methanol-d, 500 MHz, and 125 MHz).
| Position | 1 | |
|---|---|---|
|
|
| |
| 1 | ||
| 2 | 125.5 | 7.27 s |
| 3 | 112.7 | |
| 4 | 120.0 | 7.52 d (8.0) |
| 5 | 121.1 | 6.92 ddd (8.0, 7.0, 1.0) |
| 6 | 123.2 | 7.10 ddd (8.0, 7.0, 1.0) |
| 7 | 111.8 | 7.47 d (7.0) |
| 8 | 130.4 | |
| 9 | 138.5 | |
| 10 | 28.3 | 3.34 overlapped/3.49 overlapped |
| 11 | 55.6 | 4.78 t (5.0) |
| 12 | 175.9 | |
| 13 | ||
| Glc-1′ | 86.8 | 5.41 d (9.0) |
| Glc-2′ | 73.8 | 3.92 t (9.0) |
| Glc-3′ | 79.1 | 3.60 t (9.0) |
| Glc-4′ | 71.6 | 3.49 overlapped |
| Glc-5′ | 80.7 | 3.55 ddd (10.0, 6.0, 2.5) |
| Glc-6′ | 62.9 | 3.67 dd (12.0, 6.0)/3.86 dd (12.0, 2.0) |
| 1″ | 135.6 | |
| 2″/6″ | 129.7 | 7.67 dd (8.5, 1.5) |
| 3″/5″ | 128.6 | 7.38 dd (8.5, 7.5) |
| 4″ | 132.9 | 7.46 tt (7.5, 1.5) |
| 7″ | 170.4 | |
All assignments were based on COSY, HSQC, and HMBC results. δH Multi (J in Hz).
Figure 2Key 1H-1H COSY () and 1H-13C HMBC () correlations for the new compounds 1, 4, and 5.
1H- and 13C-NMR spectroscopic data of compounds 4 and 5 (δ in ppm, pyridine-d5, 500 MHz, and 125 MHz).
| Position | 4 | 5 | ||
|---|---|---|---|---|
|
| δH
| δC |
| |
| 2 | 107.6 | 107.20 | ||
| 3 | 42.4 | 3.66 q (14.0) | 41.72 | 3.64 overlapped |
| 4 | 194.3 | 195.08 | ||
| 5 | 160.6 | 159.37/159.45 | ||
| 6 | 94.8 | 6.12 d (1.5) | 93.84/82.78 | 6.14 d (2.0)/6.25 d (2.0) |
| 7 | 173.5 | 101.42/101.56 | ||
| 8 | 92.7 | 6.49 d (1.5) | 92.20/92.58 | 6.81 d (2.0)/6.76 d (2.0) |
| 9 | 174.2 | 173.34/173.19 | ||
| 10 | 102.1 | 168.40/168.46 | ||
| 1′ | 126.1 | 125.11 | ||
| 2′/6′ | 132.9 | 7.57 d (8.5) | 132.38 | 7.54 d (8.5)/7.51 d (8.5) |
| 3′/5′ | 116.2 | 7.05 d (8.5) | 115.71/115.68 | 7.06 d (8.5)/7.04 d (8.5) |
| 4′ | 158.1 | 157.68 | ||
| Glc-1″ | 104.48/104.53 | 5.68 d (7.5)/5.62 d (7.5) | ||
| Glc-2″ | 74.57 | 4.34 overlapped | ||
| Glc-3″ | 78.25 | 4.34 overlapped | ||
| Glc-4″ | 70.85/70.92 | 4.34 overlapped | ||
| Glc-5″ | 78.91/78.98 | 4.10 m | ||
| Glc-6″ | 61.96/62.01 | 4.34 overlapped/4.52 m | ||
| 3′-OMe | 55.7 | 3.56 s | 55.48/55.54 | 3.55 s/3.60 s |
All assignments were based on COSY, HSQC, and HMBC results. δH Multi (J in Hz).
Figure 3The cell viability of active compounds in A2780 human ovarian cancer cell line. Cisplatin was used as a positive control. The results are presented as mean standard ± SD and processed by using a one-way ANOVA. * p < 0.05 in comparison to control (0 μM).
The cytotoxicity of compounds 1−22 isolated from Pueraria Flos against human ovarian cell lines A2780 and IOSE80PC.
| Compound | IC50 (μM) | |
|---|---|---|
| A2780 | IOSE80PC | |
|
| 9.99 ± 0.98 | >100 |
|
| 25.63 ± 1.80 | >100 |
|
| 48.67 ± 0.31 | >100 |
|
| 57.45 ± 3.08 | >100 |
|
| 71.24 ± 11.29 | >100 |
|
| 48.54 ± 1.97 | >100 |
|
| 23.72 ± 2.54 | >100 |
|
| 7.36 ± 0.58 | 65.84 ± 1.60 |
| Cisplatin | 10.73 ± 0.81 | 12.78 ± 0.55 |
| Quercetin | 19.45 ± 2.92 | >100 |
IC50 value is defined as the concentration that reduces cell number by 50% compared to control cultures. Compounds 1–7, 9, 13, 15, 18–20, and 22 were not active (IC50 > 100 μM) in A2780 cells. The inactive compounds were not tested on IOSE80PC.